The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial.
Ono M., Chichareon P., Tomaniak M., Kawashima H., Takahashi K., Kogame N., Modolo R., Hara H., Gao C., Wang R., Walsh S., Suryapranata H., da Silva PC., Cotton J., Koning R., Akin I., Rensing BJWM., Garg S., Wykrzykowska JJ., Piek JJ., Jüni P., Hamm C., Steg PG., Valgimigli M., Windecker S., Storey RF., Onuma Y., Vranckx P., Serruys PW.
BACKGROUND: The efficacy of antiplatelet therapies following percutaneous coronary intervention (PCI) may be affected by body mass index (BMI). METHODS AND RESULTS: This is a prespecified subgroup analysis of the GLOBAL LEADERS trial, a prospective, multicenter, open-label, randomized controlled trial in an all-comer population undergoing PCI, comparing the experimental strategy (23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy [DAPT]) with a reference regimen (12-month aspirin monotherapy following 12-month DAPT). A total of 15,968 patients were stratified by baseline BMI with prespecified threshold of 27 kg/m2. Of those, 6973 (43.7%) patients with a BMI